WARNING: HEPATOTOXICITY Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended. See "Warnings ...+
VOTRIENT Nearly Tripled Median PFS vs Placebo1
CI, confidence interval; GIST, gastrointestinal stromal tumors; HR, hazard ratio; PFS, progression-free survival.
Study Design: Randomized, double-blind, placebo-controlled, multicenter, phase 3 trial to evaluate the efficacy and safety of VOTRIENT in patients (N=369) with advanced soft tissue sarcoma. The primary end point was PFS, while the secondary end points were overall survival, response rate, and safety. The phase 3 trial population excluded patients with adipocytic sarcoma or GIST. Patients were randomized (2:1) to receive either VOTRIENT 800 mg once daily or placebo. The study included patients with leiomyosarcoma receiving VOTRIENT (n=109) or placebo (n=49), patients with synovial sarcoma receiving VOTRIENT (n=25) or placebo (n=13), and patients with “other soft tissue sarcoma” receiving VOTRIENT (n=112) or placebo (n=61).1,2
- VOTRIENT demonstrated significant improvement in PFS with median PFS of 4.6 months vs 1.6 months with placebo1
- VOTRIENT demonstrated a 65% reduced risk of progression or death with a median PFS of 4.6 months vs 1.6 months with placebo (HR=0.35 [95% CI, 0.26-0.48], P<0.001)1
Highlights from Important Safety Information
- Increases in serum transaminase levels and bilirubin were observed. Severe and fatal hepatotoxicity has occurred. Measure liver chemistries before the initiation of treatment and regularly during treatment
VOTRIENT Advanced STS FAQ Video: Efficacy
View this short video in which Dr Trent answers a frequently asked question about the efficacy of VOTRIENT.
Use in Multiple Advanced STS Subtypes
VOTRIENT Demonstrated PFS Benefit in Multiple Advanced STS Subtypes1
Limitation of Use: The efficacy of VOTRIENT for the treatment of patients with adipocytic STS or GIST has not been demonstrated.
CI, confidence interval; GIST, gastrointestinal stromal tumors; HR, hazard ratio; PFS, progression-free survival.
a The efficacy of VOTRIENT has not been demonstrated in adipocytic STS or GIST.
b "Other soft tissue sarcoma" subgroups included tumors of uncertain differentiation, fibroblastic and so-called fibrohistiocytic tumors, undifferentiated sarcoma not otherwise specified, malignant peripheral nerve stromal tumors, vascular tumors, and other.3
- Leiomyosarcoma: Median PFS 4.6 months for VOTRIENT (n=109) vs 1.9 months for placebo (n=49) (HR=0.37 [95% CI, 0.23-0.60])1
- Synovial sarcoma: Median PFS 4.1 months for VOTRIENT (n=25) vs 0.9 months for placebo (n=13)
(HR=0.43 [95% CI, 0.19-0.98])1
- “Other soft tissue sarcoma” subgroups: Median PFS 4.6 months for VOTRIENT (n=112) vs 1.0 month for placebo (n=61) (HR=0.39 [95% CI, 0.25-0.60])1
- "Other soft tissue sarcoma" subgroups included tumors of uncertain differentiation, fibroblastic and so-called fibrohistiocytic tumors, undifferentiated sarcoma not otherwise specified, malignant peripheral nerve stromal tumors, vascular tumors, and other3
Highlights from Important Safety Information
- Prolonged QT intervals and torsades de pointes have been observed. Use with caution in patients at higher risk of developing QT interval prolongation. Monitoring electrocardiograms and electrolytes should be considered
Clinical Perspectives in STS: Dr. Agulnik Video
Watch a video of Dr Agulnik review the case of a patient undergoing advanced soft tissue sarcoma treatment with VOTRIENT.
Clinical Perspectives in Advanced STS: Dr Trent Video
Watch a video of Dr Trent review the case of a patient undergoing advanced soft tissue sarcoma treatment with VOTRIENT.
VOTRIENT Advanced STS FAQ Video: Subtypes
View this short video in which Dr Trent answers a frequently asked question about the subtypes of VOTRIENT.
Overall Response & Overall Survival
Phase 3 Secondary End Point Results For VOTRIENT vs Placebo
† Confirmed response per RECIST (Response Evaluation Criteria in Solid Tumors) by independent radiologist assessment.
- No complete responses were observed in either treatment arm1
- The median duration of response for VOTRIENT was 9 months (95% CI, 3.9-9.2)1
- The efficacy of VOTRIENT for the treatment of patients with adipocytic STS or GIST has not been demonstrated1
- The median overall survival was 12.6 months for VOTRIENT and 10.7 months for placebo (HR=0.87 [95% CI, 0.67-1.12])1
- OS was not statistically significant vs the control arm. Patients who progressed were allowed to cross over.
Highlights from Important Safety Information
- Cardiac dysfunction such as congestive heart failure and decreased left ventricular ejection fraction (LVEF) have occurred. Monitor blood pressure and manage hypertension promptly. Baseline and periodic evaluation of LVEF is recommended in patients at risk of cardiac dysfunction
Phase 3 Trial Design
VOTRIENT was FDA approved based on a phase 3 trial, which included 369 patients (VOTRIENT, n=246; placebo, n=123).1,2
Objective: To evaluate the efficacy and safety of VOTRIENT in patients with advanced soft tissue sarcoma who received prior chemotherapy, including anthracycline treatment, or were unsuited for such therapy1
- The phase 3 trial population excluded patients with adipocytic sarcoma or GIST1
Primary end point: Evaluate and compare 2 treatment arms (VOTRIENT vs placebo) for PFS. PFS was assessed by independent radiological review.1
Secondary end points: Overall survival, PFS in the eligible histology types (leiomyosarcoma, synovial sarcoma, and other eligible histologies), overall response rate, and duration of response.3
- “Other eligible histologies” included tumors of uncertain differentiation, fibroblastic and so-called fibrohistiocytic tumors, undifferentiated sarcoma not otherwise specified, malignant peripheral nerve stromal tumors, vascular tumors, and other3
PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; WHO, World Health Organization.
* Until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.
Patient Characteristics in the Phase 3 Trial
mTOR, mammalian target of rapamycin; WHO, World Health Organization.
a This includes systemic therapy for neoadjuvant, adjuvant, maintenance, and advanced disease.
VOTRIENT Was Studied in Multiple Sarcoma Subtypes¹
Soft tissue sarcoma subtypes included leiomyosarcoma, synovial sarcoma, and "other soft tissue sarcoma".1‡
GIST, gastrointestinal stromal tumor; MFH, malignant fibrous histiocytoma; MPNST, malignant peripheral nerve stromal tumors; N/A, not applicable; WHO, World Health Organization.
‡ GIST and adipocytic sarcomas were not included.1
a Tumor type and tumor subtype are from the WHO classification of soft tissue sarcoma 2002 (modified June 2008, refer to RAP).3
- Votrient [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2017.
- van der Graaf WTA, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879-1886.
- Data on file. Study VEG110727. Novartis Pharmaceuticals Corp; 2011.
VOTRIENT® (pazopanib) tablets is indicated for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.
Limitation of Use: The efficacy of VOTRIENT for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.
Important Safety Information for VOTRIENT® (pazopanib) tablets
Hepatic Toxicity and Hepatic Impairment: Severe and fatal hepatotoxicity has occurred. Patients older than 65 years are at an increased risk. Increases in serum transaminase levels (ALT, AST) and bilirubin were observed. Transaminase elevations occur early in the course of treatment (92.5% of all transaminase elevations of any grade occurred in the first 18 weeks). In patients with preexisting moderate hepatic impairment, the starting dose of VOTRIENT should be reduced to 200 mg per day or alternatives to VOTRIENT should be considered. Treatment with VOTRIENT is not recommended in patients with severe hepatic impairment. Concomitant use of VOTRIENT and simvastatin increases the risk of ALT elevations and should be undertaken with caution [see Drug Interactions]. Before the initiation of treatment and regularly during treatment, monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended.
QT Prolongation and Torsades de Pointes: Prolonged QT intervals and arrhythmias, including torsades de pointes, have occurred. Use with caution in patients with a history of QT interval prolongation, patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease. Baseline and periodic monitoring of electrocardiograms and maintenance of electrolytes (eg, calcium, magnesium, and potassium) within the normal range should be performed.
Cardiac Dysfunction: Cardiac dysfunction, such as congestive heart failure (CHF) and decreased left ventricular ejection fraction (LVEF), has occurred. In the randomized STS trial, in patients who had baseline and follow-up LVEF measurements, myocardial dysfunction occurred in 11% (16/142) of patients on VOTRIENT compared to 5% (2/40) of patients on placebo. One percent (3/240) of patients on VOTRIENT had CHF, which did not resolve in 1 patient. Monitor blood pressure (BP), and manage promptly using a combination of antihypertensive therapy and dose modification of VOTRIENT (interruption and reinitiation at a reduced dose based on clinical judgment). Carefully monitor patients for clinical signs or symptoms of CHF. Baseline and periodic evaluation of LVEF is recommended in patients at risk of cardiac dysfunction, including previous anthracycline exposure.
Hemorrhagic Events: Hemorrhagic events have occurred and can be fatal. In the randomized STS trial, 22% (53/240) of patients treated with VOTRIENT compared to 8% (10/123) treated with placebo experienced at least 1 hemorrhagic event. The most common hemorrhagic events were epistaxis (8%), mouth hemorrhage (3%), and anal hemorrhage (2%). VOTRIENT should not be used in patients who have a history of hemoptysis, cerebral, or clinically significant gastrointestinal (GI) hemorrhage in the past 6 months.
Arterial Thromboembolic Events: Arterial thromboembolic events have occurred and can be fatal. In the randomized STS trial, 2% (4/240) of patients receiving VOTRIENT experienced myocardial infarction or ischemia, 0.4% (1/240) had a cerebrovascular accident, and there were no incidents of transient ischemic attack. No arterial thromboembolic events were reported in patients who received placebo. Use with caution in patients who are at increased risk for these events or have a history of these events. Do not use VOTRIENT in patients who have had an arterial thromboembolic event in the past 6 months.
Venous Thromboembolic Events (VTEs): VTEs have occurred, including venous thrombosis and fatal pulmonary emboli. In the randomized STS trial, VTEs were reported in 5% of patients treated with VOTRIENT compared to 2% with placebo. Fatal pulmonary embolus occurred in 1% (2/240) of STS patients receiving VOTRIENT and in no patients receiving placebo. Monitor for signs and symptoms.
Thrombotic Microangiopathy (TMA): TMA, including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), has been reported in clinical trials of VOTRIENT as monotherapy, in combination with bevacizumab, and in combination with topotecan. VOTRIENT is not indicated for use in combination with other agents. Six of the 7 TMA cases occurred within 90 days of the initiation of VOTRIENT. Improvement of TMA was observed after treatment was discontinued. Monitor for signs and symptoms of TMA. Permanently discontinue VOTRIENT in patients developing TMA. Manage as clinically indicated.
GI Perforation and Fistula: In STS trials, GI perforation or fistula occurred in 1% (4/382) of patients receiving VOTRIENT. Fatal perforations occurred in 0.3% (1/382) of these patients. Use with caution in patients at risk for these events, and monitor for signs and symptoms.
Interstitial Lung Disease (ILD)/Pneumonitis: ILD/pneumonitis, which can be fatal, has been reported in 0.1% of patients in the clinical trials treated with VOTRIENT. Monitor patients for ILD/pneumonitis, and discontinue VOTRIENT if symptoms of ILD or pneumonitis develop.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS has been reported and may be fatal. Permanently discontinue VOTRIENT in patients developing RPLS.
Hypertension (HTN): HTN, including hypertensive crisis, has occurred in clinical trials. HTN occurs early in the course of treatment (approximately 40% of cases occurred by Day 9, and 90% of cases occurred in the first 18 weeks). BP should be well controlled prior to initiating VOTRIENT, monitored early after starting treatment (no longer than 1 week), and frequently thereafter. Treat increased BP promptly with standard antihypertensive therapy and dose reduction or interruption of VOTRIENT, as clinically warranted. Discontinue VOTRIENT if there is evidence of hypertensive crisis or if HTN is severe and persistent despite antihypertensive therapy and dose reduction of VOTRIENT. Approximately 1% of patients required permanent discontinuation of VOTRIENT because of HTN.
Wound Healing: VOTRIENT may impair wound healing. Interruption of therapy is recommended in patients undergoing surgical procedures. Treatment with VOTRIENT should be stopped at least 7 days prior to scheduled surgery. VOTRIENT should be discontinued in patients with wound dehiscence.
Hypothyroidism: Hypothyroidism was reported in 5% (11/240) of patients treated with VOTRIENT in the randomized STS trial and in no patients receiving placebo. Monitoring of thyroid function tests is recommended.
Proteinuria: In the randomized STS trial, proteinuria was reported as an adverse reaction in 1% (2/240) of patients, and nephrotic syndrome was reported in 1 patient treated with VOTRIENT compared to none in patients receiving placebo. Treatment was withdrawn in the patient with nephrotic syndrome. Monitor urine protein at baseline and periodically as clinically indicated. Interrupt treatment for 24-hour urine protein ≥3 grams, and discontinue for repeat episodes despite dose reductions.
Infection: Serious infections (with or without neutropenia), some with fatal outcomes, have been reported. Monitor for signs and symptoms, and treat active infection promptly. Consider interruption or discontinuation of VOTRIENT.
Increased Toxicity With Other Cancer Therapy: VOTRIENT is not indicated for use in combination with other agents. Increased toxicity and mortality have been observed in clinical trials administering VOTRIENT in combination with lapatinib or with pemetrexed. The fatal toxicities observed included pulmonary hemorrhage, GI hemorrhage, and sudden death. A safe and effective combination dose has not been established with these regimens.
Increased Toxicity in Developing Organs: The safety and effectiveness of VOTRIENT in pediatric patients have not been established. VOTRIENT is not indicated for use in pediatric patients. Animal studies have demonstrated pazopanib can severely affect organ growth and maturation during early postnatal development, and resulted in toxicity to the lungs, liver, heart, and kidney, and in death. VOTRIENT may potentially cause serious adverse effects on organ development in pediatric patients, particularly in patients younger than 2 years of age.
Females and Males of Reproductive Potential: VOTRIENT can cause fetal harm when administered to a pregnant woman based on animal reproduction studies and its mechanism of action. In animal developmental and reproductive toxicology studies, oral administration of pazopanib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity, and abortion at systemic exposures lower than that observed at the maximum recommended human dose of 800 mg.
Verify pregnancy status of females of reproductive potential prior to starting treatment with VOTRIENT. Advise females of reproductive potential to use effective contraception during treatment and for at least 2 weeks after the last dose of VOTRIENT. To avoid potential drug exposure to pregnant partners and female partners of reproductive potential, advise male patients (including those who have had vasectomies) with female partners of reproductive potential to use condoms during treatment with VOTRIENT and for at least 2 weeks after the last dose. VOTRIENT may impair fertility in females and males of reproductive potential while receiving treatment. Because of the potential for serious adverse reactions in breastfed infants from VOTRIENT, advise a lactating woman not to breastfeed during treatment with VOTRIENT and for 2 weeks after the final dose.
Diarrhea: Diarrhea occurred frequently and was predominantly mild to moderate in severity. Patients should be advised how to manage mild diarrhea and to notify their health care provider if moderate to severe diarrhea occurs so appropriate management can be implemented to minimize its impact.
Pneumothorax: Pneumothorax has occurred (8/240 STS patients [3%] treated with VOTRIENT vs 0% in the placebo group).
Bradycardia: In the randomized trial of VOTRIENT for the treatment of STS, bradycardia based on vital signs (<60 beats per minute) was observed in 19% (45/238) of patients treated with VOTRIENT and in 4% (5/121) of patients on the placebo arm.
Drug Interactions: Coadministration with strong CYP3A4 inhibitors (eg, ketoconazole, ritonavir, clarithromycin) increases concentrations of pazopanib and should be avoided, but, if warranted, reduce the dose of VOTRIENT to 400 mg. Avoid grapefruit and grapefruit juice.
Concomitant use of strong CYP3A4 inducers (eg, rifampin) should be avoided due to the potential to decrease concentrations of pazopanib. VOTRIENT should not be used in patients who cannot avoid chronic use of CYP3A4 inducers.
Concomitant treatment with strong inhibitors of P-glycoprotein (PgP) or breast cancer resistance protein (BCRP) should be avoided due to risk of increased exposure to pazopanib.
CYP Substrates: Concomitant use of VOTRIENT with agents with narrow therapeutic windows that are metabolized by CYP3A4, CYP2D6, or CYP2C8 is not recommended. Coadministration may result in inhibition of the metabolism of these products and create the potential for serious adverse events.
Concomitant use of VOTRIENT and simvastatin increases the incidence of ALT elevations. If a patient develops ALT elevations, follow dosing guidelines for VOTRIENT, consider alternatives to VOTRIENT, or consider discontinuing simvastatin. There are insufficient data to assess the risk of concomitant administration of alternative statins and VOTRIENT.
Drugs That Raise Gastric pH: Avoid concomitant use of VOTRIENT with drugs that raise gastric pH (eg, esomeprazole) due to the potential to decrease concentrations of pazopanib. Consider short-acting antacids in place of proton pump inhibitors (PPIs) and H2 receptor antagonists. Separate antacid and pazopanib dosing by several hours.
Adverse Reactions in the Randomized STS Trial: A dose interruption was required for 58% of patients on VOTRIENT. The VOTRIENT dose was reduced for 38% of patients. Therapy was discontinued due to adverse reactions for 17% of patients who received VOTRIENT.
The most common adverse reactions (≥20%) in patients who received VOTRIENT vs placebo were fatigue (65% vs 48%), diarrhea (59% vs 15%), nausea (56% vs 22%), decreased weight (48% vs 15%), HTN (42% vs 6%), decreased appetite (40% vs 19%), hair color changes (39% vs 2%), vomiting (33% vs 11%), tumor pain (29% vs 21%), dysgeusia (28% vs 3%), headache (23% vs 8%), musculoskeletal pain (23% vs 20%), myalgia (23% vs 9%), GI pain (23% vs 9%), and dyspnea (20% vs 17%).
Laboratory abnormalities occurring in >10% of STS patients and more commonly (≥5%) in patients receiving VOTRIENT vs placebo included increases in AST (51% vs 22%), ALT (46% vs 18%), glucose (45% vs 35%), alkaline phosphatase (32% vs 23%), total bilirubin (29% vs 7%), and potassium (16% vs 11%); decreases in albumin (34% vs 21%) and sodium (31% vs 20%); and leukopenia (44% vs 15%), lymphocytopenia (43% vs 36%), thrombocytopenia (36% vs 6%), and neutropenia (33% vs 7%).
In a pooled analysis of VOTRIENT clinical trials, East Asian patients had a higher frequency of neutropenia, thrombocytopenia, and palmar-plantar erythrodysesthesia syndrome than non-East Asian patients. (See Adverse Reactions, Section 6.1, in complete Prescribing Information.)